Ciaco A, Papi C, Capurso L
Servizio di Gastroenterologia ed Endoscopia Digestiva, Ospedale S. Filippo Neri, Roma.
Minerva Gastroenterol Dietol. 1992 Jul-Sep;38(3):153-9.
The aim of the present study was to evaluate the role of sulglycotide, a molecule with gastroprotective properties, in monotherapy and in association with H2-antagonists in the maintenance treatment of duodenal ulcer. The study was performed using a fully randomized experimental design. Following endoscopic confirmation, 626 patients with healed duodenal ulcer were treated for 6 months with sulglycotide 200 mg tid (293 patients) or sulglycotide + H2-antagonists (333 patients). After 2, 4 and 6 months patients underwent a clinical control whereas an endoscopic control was performed after 6 months. The cumulative percentage of recidivation was 3.6% in the sulglycotide + H2-antagonist treated group, whereas the group treated with sulglycotide alone showed a recidivation rate of 15.4% (p < 0.001). These findings suggest the utility of combined sulglycotide and H2-antagonist treatment in the maintenance therapy for duodenal ulcer.
本研究的目的是评估具有胃保护特性的分子硫糖铝在十二指肠溃疡维持治疗中单独使用以及与H2拮抗剂联合使用的作用。该研究采用完全随机实验设计。在内镜检查确认后，626例十二指肠溃疡已愈合的患者接受了6个月的治疗，其中293例患者每日三次服用200mg硫糖铝，333例患者服用硫糖铝+H2拮抗剂。在2、4和6个月时对患者进行临床检查，而在6个月后进行内镜检查。硫糖铝+H2拮抗剂治疗组的累积复发率为3.6%，而单独使用硫糖铝治疗组的复发率为15.4%（p<0.001）。这些发现表明硫糖铝和H2拮抗剂联合治疗在十二指肠溃疡维持治疗中的实用性。
